[Federal Register: August 20, 1998 (Volume 63, Number 161)] [Notices] [Page 44630] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr20au98-66] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting with be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel, Preclinical Evaluation of Intermediate Endpoints and their Modulation by Chemopreventive Agents. Date: September 14, 1998. Time: 3:00 PM to 5:30 PM. Agenda: To review and evaluate grant applications. Place: 6130 Executive Blvd. 6th Floor, Rockville, MD 20852. Contact Person: Lalita D. Palekar, Scientific Review Administrator, Special Review, Referral and Resources Branch, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6130 Executive Boulevard EPN-622B, Rockville, MD 20892-7405, 301/496-7575. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: August 14, 1998. LaVerne Y. Stringfield, Committee Management Officer, NIH. [FR Doc. 98-22410 Filed 8-19-98; 8:45 am] BILLING CODE 4140-01-M